US immunology specialist Acelyrin (Nasdaq: SLRN) lost a whopping 54% of its stock market value on Tuesday.
The Californian company - which was riding high in May on raising $540 million in an initial public offering - had announced top-line results from Part B of a Phase IIb/III trial evaluating izokibep for the treatment of moderate-to-severe hidradenitis suppurativa (HS).
The primary endpoint of HiSCR75 (hidradenitis suppurativa clinical response) at week 16 did not meet statistical significance. Acelyrin’s cause was not helped by a high drop-out rates.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze